Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-014-5 | CAS number: 2314-97-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
- Endpoint:
- specific investigations: other studies
- Remarks:
- Acute cardiac sensitization
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 17 Feb 2006 to 23 Mar 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The substance was administered via muzzle-only inhalation exposure (vapor) as acute exposures at concentrations of 2.0%, 3.5%, 5.0% and 7.5% (20,000, 35,000, 50,000 and 75,000 ppm, respectively). One group of 6 male dogs was used on this study, which received the 4 doses with intervals of at least 48 hours. Each dog served as its own control. For the 2.0%, 3.5% and 5.0% groups, animals were administered a predetermined dose of epinephrine as a bolus injection via a cephalic vein approximately 5 minutes prior to exposure to the test article. Five minutes after exposure to the test article began, the animals were administered a challenge dose of epinephrine. For the 7.5% group, exposure to the test article was initiated and then 3 doses of epinephrine were administered 5 minutes apart. Following the final exposure, all dogs were returned to stock. All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed prior to initiation of each exposure, continually during the exposure and immediately following each exposure period. Detailed physical examinations were performed and body weights were collected prior to the first day of exposures and at the completion of all exposures. Electrocardiographic data were recorded continuously throughout the pre-exposure epinephrine dosing, exposure to the test gas and for 5 minutes following administration of the challenge epinephrine dose (total of approximately 17 minutes).
- GLP compliance:
- yes
- Type of method:
- in vivo
- Endpoint addressed:
- other: Acute cardiac sensitization
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Identity: Proprietary Refrigerant Blend containing 29.8 to 31.3% CF3I
- Source and lot/batch No.of test material: Honeywell, Buffalo, New York
- Physical appearance: clear gas
- Storage condition of test material: Room temperature - Species:
- dog
- Strain:
- Beagle
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: WIL Research Laboratories, LLC stock dog colony
- Age at study initiation: 6.5 to 9 months old at the initiation of exposure.
- Weight at study initiation: 7.9 to 10.3 kg
- Housing: The animals were housed individually in clean, stainless steel cages elevated above stainless steel cage pans that were cleaned daily. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The animals were allowed regular opportunity for exercise and social interaction in accordance with the standard operating procedures at WIL Research Laboratories, LLC, and the Animal Welfare Act (9 CFR Part 3).
- Diet: Approximately 400 g of PMI Nutrition International, LLC, Certified Canine LabDiet 5007, was offered 1 to 2 hours per day. Feed was withheld during exposure periods.
- Water: Reverse osmosis-treated (on-site) drinking water, delivered by an automatic watering system, was provided ad libitum throughout the study period. Water was withheld during exposure periods.
- Acclimation period: Animals considered suitable for the study were housed for an appropriate acclimation/pretest period. During this period, each animal was observed twice daily for mortality and changes in general appearance or behavior. Fecal samples were collected prior to the initiation of dose administration and checked for parasites; none were present. Individual body weights were recorded and detailed physical examinations were performed periodically during the pretest period. Food consumption and electrocardiographic data were also recorded for pretest animals prior to the initiation of dose administration. During the acclimation period, each dog was acclimated to exposure/restraint for several 10 to 20 minute periods. At least 10 acclimation sessions/dog were conducted.
- All animals were immunized prior to arrival at WIL Research Laboratories, LLC. The immunizations included rabies, Bordetella, distemper, adenovirus type 2, Leptospira spp, parvovirus, parainfluenza and oral papilloma virus.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.2 to 21.7
- Humidity (%): 32.8 to 52.5
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Vehicle:
- air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Each animal was exposed individually using a muzzle-only exposure apparatus operated under dynamic conditions to supply the target concentration of the test article vapor and a minimum oxygen content of 19%. The mask used in the muzzle-only exposure system is a WIL-designed and manufactured, dual-port mask constructed of Neoprene®, nylon straps and “hook-and-loop” fastening material. Exposures were conducted using a muzzle-only system consisting of a mask connected to 3-way valve connected to a gas bag containing the appropriate test article mixture.
- Method of holding animals in test chamber: Each dog was comfortably restrained using a canvas sling with the appropriate ECG (limb) leads attached.
- Source and rate of air: The control atmosphere (the first 7 minutes of each exposure) was filtered air supplied from an in-house source.
- Method of conditioning air: Oxygen was added to each gas bag as needed to maintain oxygen content above 19%.
TEST ATMOSPHERE
- Prior to each exposure, samples were analyzed from each bag using a gas chromatographic method to assure that the atmosphere was at the target concentration.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Prior to each exposure, samples were analyzed from each bag using a gas chromatographic method to assure that the atmosphere was at the target concentration.
- Duration of treatment / exposure:
- 10 minutes for the 2, 3.5 and 5% dose-groups and 20 min for 7.5%
- Frequency of treatment:
- - One exposure/ dose (4 treatments in total), separated by a minimum of 48 hours.
- One pre-exposure dose and one challange dose of Epinephrine (3 challange doses for the 7.5% dose). - Post exposure period:
- at least 48 hours between the doses, 7 days after the final dose.
- Dose / conc.:
- 20 000 ppm
- Remarks:
- Equivalent to 2%
- Dose / conc.:
- 35 000 ppm
- Remarks:
- Equivalent to 3.5%
- Dose / conc.:
- 50 000 ppm
- Remarks:
- Equivalent to 5%
- Dose / conc.:
- 75 000 ppm
- Remarks:
- Equivalent to 7.5%
- No. of animals per sex per dose:
- - 20000, 35000, 50000 ppm: 6
- 75000 ppm: 5 - Control animals:
- yes
- Details on study design:
- This species and breed of animal is recognized as appropriate for cardiac function studies. The beagle dog was used because it is a widely used breed for which significant historical control data are available. The number of animals selected was the minimum needed to yield scientifically meaningful data.
ORGANISATION AND TREATMENT REGIMEN
Prior to exposure (during the pre-study acclimation period), an individual response to intravenous epinephrine administration was established for each individual dog using epinephrine doses starting at 2 μg/kg and increasing to 3, 4, 6 or 8 μg/kg, if necessary. The epinephrine doses were administered as a bolus injection (<5 seconds) via the cephalic vein. Time between escalating doses of epinephrine was at least 5 minutes or until the ECG returned to baseline. During this phase of the study, the dogs were exposed to air only via the muzzle-only exposure apparatus. The information gathered was used to select dogs for use on study and to establish the specific level of epinephrine each dog would receive during the test article exposure phase of the study. The epinephrine level selected for an individual dog was the highest dose level tested during the pre-study evaluation that did not elicit significant ECG findings (e.g., PVC). - Examinations:
- CLINICAL OBSERVATIONS AND SURVIVAL
All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity. Clinical examinations were performed on each dog prior to initiation of each exposure, continually during the exposure period and following each exposure upon return to their home cages. Detailed physical examinations were conducted on all animals on the day prior to the first day of exposure and on the last exposure day.
BODY WEIGHTS
Individual body weights were recorded on the first day of exposure and on the last day of exposure. Body weight changes were calculated for the corresponding intervals.
ELECTROCARDIOGRAPHIC EXAMINATIONS
Electrocardiograms (ECG) were recorded with a Burdick electrocardiograph. Modified leads I, II and III were used for electrocardiogram collection; ECG electrodes were placed on each limb. For the 2.0%, 3.5% and 5.0% test article exposures, ECG were recorded continuously throughout the pre-exposure epinephrine dosing, exposure to the test gas and for 5 minutes following administration of the challenge epinephrine dose (total of approximately 17 minutes). For the 7.5% test article exposure, ECG were collected for the entire exposure period (total of approximately 21 minutes). The points at which epinephrine was administered and when exposure to the test article was initiated were clearly marked on each ECG recording.
ECG recordings taken during exposure to the test article and after administration of the challenge epinephrine dose were compared to the ECG recordings made after administration of the pre-exposure epinephrine dose that was given in the absence of test article. - Details on results:
- CLINICAL OBSERVATIONS AND SURVIVAL
All animals survived to study termination. There were no test article-related clinical observations. All clinical findings in the test article-treated groups were limited to single animals, were not observed consistently and/or were common findings for laboratory dogs of this age and breed.
BODY WEIGHTS
Body weights were unaffected by test article administration. There were no remarkable changes over the course of the study.
ELECTROCARDIOGRAPHIC EXAMINATIONS
Positive cardiac responses were noted for 0/6, 1/6 and 3/6 animals in the 20,000, 35,000 and 50,000 ppm groups, respectively. In the 75, 000 ppm group where the challenge doses of epinephrine were administered in ascending order, positive responses were noted for 0/5 animals at 0.2 μg/kg, 1/5 animals at 1.0 μg/kg and 2/4 animals at 2.0 μg/kg. The 2.0 μg/kg challenge dose of epinephrine was not administered to one animal due to the magnitude of effect noted following administration of the 1.0 μg/kg challenge dose. Positive responses were noted as occurrences of ventricular fibrillation, premature ventricular contractions or ventricular tachycardia. - Conclusions:
- Based on the results of this study, muzzle-only vapor exposure to 35,000, 50,000 and 75,000 ppm Proprietary Refrigerant Blend in beagle dogs followed by administration of epinephrine resulted in episodes of premature ventricular contractions indicative of cardiac sensitization. Therefore, the no-observed-effect level (NOEL) was 20,000 ppm when maximum epinephrine injections were administered. In the study, at 75,000 ppm, a dose level of 0.2 μg/kg of epinephrine also did not cause cardiac arrhythmia.
- Executive summary:
The objective of this study was to evaluate the cardiac sensitization potential of the test substance during acute inhalation exposure to various concentrations of the test article. The test article contained 29.8 to 31.3% CF3I. Cardiac sensitization refers to the potential for the test article to increase sensitivity of the heart to the pharmacological effects of epinephrine. The substance was administered via muzzle-only inhalation exposure (vapor) as acute exposures at concentrations of 2.0%, 3.5%, 5.0% and 7.5% (20,000, 35,000, 50,000 and 75,000 ppm, respectively). One group of 6 male dogs was used on this study. Each dog served as its own control. For the 2.0%, 3.5% and 5.0% groups, animals were administered a predetermined dose of epinephrine as a bolus injection via a cephalic vein approximately 5 minutes prior to exposure to the test article. Five minutes after exposure to the test article began, the animals were administered a challenge dose of epinephrine. For the 7.5% group, exposure to the test article was initiated and then 3 doses of epinephrine were administered 5 minutes apart. Following the final exposure, all dogs were returned to stock. All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed prior to initiation of each exposure, continually during the exposure and immediately following each exposure period. Detailed physical examinations were performed and body weights were collected prior to the first day of exposures and at the completion of all exposures. Electrocardiographic data were recorded continuously throughout the pre-exposure epinephrine dosing, exposure to the test gas and for 5 minutes following administration of the challenge epinephrine dose (total of approximately 17 minutes).
All animals survived to study termination. There were no test article-related clinical observations. Body weights were unaffected by test article administration. Positive cardiac responses were noted for 0/6, 1/6 and 3/6 animals in the 20,000, 35,000 and 50,000 ppm groups, respectively. In the 75, 000 ppm group where the challenge doses of epinephrine were administered in ascending order, positive responses were noted for 0/5 animals at 0.2 μg/kg, 1/5 animals at 1.0 μg/kg and 2/4 animals at 2.0 μg/kg.
Based on the results of this study, muzzle-only vapor exposure to 35,000, 50,000 and 75,000 ppm Proprietary Refrigerant Blend in beagle dogs followed by administration of epinephrine resulted in episodes of premature ventricular contractions indicative of cardiac sensitization. Therefore, the no-observed-effect level (NOEL) was 20,000 ppm when maximum epinephrine injections were administered. In the study, at 75,000 ppm, a dose level of 0.2 μg/kg of epinephrine also did not cause cardiac arrhythmia.
Reference
Description of key information
Based on the results of this study, muzzle-only vapor exposure to 35,000, 50,000 and 75,000 ppm Proprietary Refrigerant Blend in beagle dogs followed by administration of epinephrine resulted in episodes of premature ventricular contractions indicative of cardiac sensitization. Therefore, the no-observed-effect level (NOEL) was 20,000 ppm when maximum epinephrine injections were administered. In the study, at 75,000 ppm, a dose level of 0.2 μg/kg of epinephrine also did not cause cardiac arrhythmia.
Additional information
Acute cardiac sensitization study in Beagle dogs with a test substance containing 29.8 to 31.3% CF3I
The objective of this study was to evaluate the cardiac sensitization potential of the test substance during acute inhalation exposure to various concentrations of the test article (WIL Research 2006). The test article contained 29.8 to 31.3% CF3I. Cardiac sensitization refers to the potential for the test article to increase sensitivity of the heart to the pharmacological effects of epinephrine. The substance was administered via muzzle-only inhalation exposure (vapor) as acute exposures at concentrations of 2.0%, 3.5%, 5.0% and 7.5% (20,000, 35,000, 50,000 and 75,000 ppm, respectively). One group of 6 male dogs was used on this study which received the 4 doses with intervals of at least 48 hours.. Each dog served as its own control. For the 2.0%, 3.5% and 5.0% groups, animals were administered a predetermined dose of epinephrine as a bolus injection via a cephalic vein approximately 5 minutes prior to exposure to the test article. Five minutes after exposure to the test article began, the animals were administered a challenge dose of epinephrine. For the 7.5% group, exposure to the test article was initiated and then 3 doses of epinephrine were administered 5 minutes apart. Following the final exposure, all dogs were returned to stock. All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed prior to initiation of each exposure, continually during the exposure and immediately following each exposure period. Detailed physical examinations were performed and body weights were collected prior to the first day of exposures and at the completion of all exposures. Electrocardiographic data were recorded continuously throughout the pre-exposure epinephrine dosing, exposure to the test gas and for 5 minutes following administration of the challenge epinephrine dose (total of approximately 17 minutes).
All animals survived to study termination. There were no test article-related clinical observations. Body weights were unaffected by test article administration. Positive cardiac responses were noted for 0/6, 1/6 and 3/6 animals in the 20,000, 35,000 and 50,000 ppm groups, respectively. In the 75, 000 ppm group where the challenge doses of epinephrine were administered in ascending order, positive responses were noted for 0/5 animals at 0.2 μg/kg, 1/5 animals at 1.0 μg/kg and 2/4 animals at 2.0 μg/kg.
Based on the results of this study, muzzle-only vapor exposure to 35,000, 50,000 and 75,000 ppm Proprietary Refrigerant Blend in beagle dogs followed by administration of epinephrine resulted in episodes of premature ventricular contractions indicative of cardiac sensitization. Therefore, the no-observed-effect level (NOEL) was 20,000 ppm when maximum epinephrine injections were administered. In the study, at 75,000 ppm, a dose level of 0.2 μg/kg of epinephrine also did not cause cardiac arrhythmia.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.